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Hematopoietic stem cells (HSCs) originate within
the aortic-gonado-mesonephros (AGM) region of
the midgestation embryo, but the cell type responsi-
ble for their emergence is unknown since critical he-
matopoietic factors are expressed in both the AGM
endothelium and its underlying mesenchyme. Here
we employ a temporally restricted genetic tracing
strategy to selectively label the endothelium, and
separately its underlying mesenchyme, during AGM
development. Lineage tracing endothelium, via an in-
ducible VE-cadherin Cre line, reveals that the endo-
thelium is capable of HSC emergence. The endothe-
lial progeny migrate to the fetal liver, and later to the
bone marrow, and are capable of expansion, self-
renewal, and multilineage hematopoietic differen-
tiation. HSC capacity is exclusively endothelial, as
ex vivo analyses demonstrate lack of VE-cadherin
Cre induction in circulating and fetal liver hematopoi-
etic populations. Moreover, AGM mesenchyme, as
selectively traced via a myocardin Cre line, is incapa-
ble of hematopoiesis. Our genetic tracing strategy
therefore reveals an endothelial origin of HSCs.
INTRODUCTION
The first site of mammalian intraembryonic hematopoiesis con-
sists of the dorsal aorta during a developmental period when it
is flanked by the gonado-mesonephric columns (the AGM re-
gion) (Godin et al., 1995; Medvinsky and Dzierzak, 1996). Within
the AGM at E10.5–11.5, hematopoietic cells can be seen at-
tached to the aorta and have been referred to as ‘‘budding’’
from this region (Garcia-Porrero et al., 1995; Jaffredo et al.,Ce1998). Whether these ‘‘budding’’ hematopoietic cells arise from
endothelium or its underlying mesenchyme is still a matter of
controversy (North et al., 1999; de Bruijn et al., 2002; Bertrand
et al., 2005). The difficulty lies in the fact that the two regions,
from a technical standpoint, are not amenable to physical sepa-
ration, and both are noted to express signaling molecules and
transcription factors critical for hematopoiesis (North et al.,
2002; Bertrand et al., 2005). In addition, while the AGM is a site
of HSC emergence, it is unable to support hematopoietic differ-
entiation (Godin et al., 1999), an attractive feature that may en-
able its application in vitro, once the specific cell type andmech-
anisms of HSC emergence are delineated.
The AGM region has been shown through numerous assays to
generate hematopoietic stem cells (HSCs), which are capable of
multilineage long-term reconstitution of irradiated hosts (Medvin-
sky and Dzierzak, 1996; Cumano et al., 2001). However, many of
these studies required ex vivo manipulations that separate tis-
sues from the circulation and their physiological milieu (Medvin-
sky and Dzierzak, 1996; Cumano et al., 2001). The majority of
analyses include either the entire AGM or its dissected subre-
gions without restriction to a specified cell type (Godin et al.,
1995; Medvinsky and Dzierzak, 1996; Cumano et al., 2001). The
complexity of investigating HSC emergence in vivo is that once
circulation is established, it is difficult to determine which embry-
onic sites contribute to later hematopoiesis and which cell types
are necessary and sufficient for the ontogeny of HSCs.
VE-cadherin, a cell-adhesion molecule with restricted endo-
thelial expression (Breier et al., 1996; Dejana et al., 1999), has
been implicated as a marker for hematopoietic cells arising
from the AGM (Nishikawa et al., 1998; Fraser et al., 2002; Fraser
et al., 2003). As many cell-surface markers are shared between
hematopoietic cells and endothelium, it has been suggested
that AGM HSCs are endothelial derived (Jaffredo et al., 1998;
de Bruijn et al., 2002; North et al., 2002; Sugiyama et al., 2003).
VE-cadherin protein was also shown to identify HSC populations
within the circulation and fetal liver (Kim et al., 2005; Taoudi et al.,ll Stem Cell 3, 625–636, December 4, 2008 ª2008 Elsevier Inc. 625
Cell Stem Cell
Endothelial Hematopoiesis2005).Whether this protein expression is a result of a ‘‘carryover’’
effect from potential endothelial progenitors or the outcome of
active VE-cadherin gene expression remains to be clarified.
The HSCs of the AGM have been demonstrated to be incapa-
ble of in situ hematopoietic differentiation (Godin et al., 1999).
Therefore, it has been postulated that AGM cells migrate to the
fetal liver for terminal differentiation, with final residence in the
adult bone marrow (Delassus and Cumano, 1996). The proof of
migration from one particular site to another has been, up to
this point, difficult to establish. The goal of this study was to uti-
lize inducible Cre/lox technology to label particular populations,
during a narrow developmental window, and lineage trace AGM
endothelial and mesenchymal progeny to their intermediate and
final destinations as well as to determine the cell type responsi-
ble for HSC emergence.
RESULTS
VE-Cadherin Lineage Labels the Vascular
and Hematopoietic AGM Population
As studies have demonstrated the expression of VE-cadherin
within the endothelium and HSCs of the AGM (North et al., 2002;
Fraser et al., 2003), we investigated whether these cells can be
labeled and traced using a constitutive VE-cadherin Cre mouse
(Alva et al., 2006) crossed to a ROSA26R (R26R) Cre reporter
line (Soriano, 1999). As noted in Figure 1A, the constitutive VE-
cadherin Cre/R26R line exhibits b-galactosidase (b-gal) labeling
of the developing vascular system at E10.5–11. At this time, the
AGM region (Figures 1B and 1C) reveals preferential labeling of
the ventral wall of the dorsal aortic endothelium, an area noted
for HSC emergence (de Bruijn et al., 2002; North et al., 2002;
Taoudi andMedvinsky, 2007). In addition, cells similar to the pre-
viously described ‘‘budding’’ HSCs are also labeled (Figure 1C,
arrows). During peak fetal liver hematopoietic capacity, there ex-
ists a stark contrast of VE-cadherin protein expression, which
appears predominantly vascular (Figure 1D), to the b-gal-labeled
(VE-cadherin lineage) populations of both hematopoietic and
endothelial cells (Figure 1E). This discrepancy between VE-
cadherin protein expression and b-gal labeling is due to the latter
depicting a historical population of hematopoietic progeny,
which were traced from a VE-cadherin+ cell type. The progeny
can also be detected in the adult bonemarrow, as demonstrated
in Figure 1F. When quantified by FACS analysis of b-gal expres-
sion, the VE-cadherin progeny constitute approximately
20%–40% of the fetal liver population and average 52% (±5%
SEM) of the adult bone marrow (Figure 1G). The demonstration
of labeled cells within definitive hematopoietic sites, in excess
of reported VE-cadherin protein expression at these sites (Quirici
et al., 2001; Kim et al., 2005; Taoudi et al., 2005), points to the
ability of earlier VE-cadherin+ cells to give rise to definitive
hematopoietic progeny. Additional support for this conclusion
is the fact that VE-cadherin progeny in the fetal liver population
express stem markers typical of this developmental time
point, while the adult bone marrow population expresses
markers of all hematopoietic lineages, including stem markers
(Figure 1H).
Figure 1. VE-Cadherin Cre Labels AGM
Endothelium and a Subset of Hematopoietic
Cells
(A–H) Constitutively active VE-cadherin Cre-
recombinase crossed to R26R results in vascular
and hematopoietic b-gal (blue) labeling. (A) E10.5
whole mount depicts b-gal expression in the vas-
culature. (B) Histological section of the E11.0
AGM demonstrates labeled endothelium (nuclear
counterstain in red). (C) The AGM endothelium
and contiguous hematopoietic cells (arrows) ex-
hibit b-gal labeling. (D) The E13.5 fetal liver demon-
strates predominantly vascular VE-cadherin pro-
tein expression (green, nuclear stain blue). (E)
VE-cadherin b-gal-labeled progeny consist of
both hematopoietic and endothelial cells in the
E13.5 fetal liver. (F) Adult bone marrow demon-
strates a significant number of labeled hematopoi-
etic cells. (G) Flow cytometry results depict per-
centage of b-gal-positive cells within E13.5 fetal
liver and adult bone marrow (per animal). (H) Fold
change of b-gal-positive cells per subpopulation
compared to total. Fetal liver HSC populations
are enriched within the b-gal population (n = 5–8,
across three litters); however, this may be due to
higher autofluorescence levels (Figure S3). The
adult bone marrow lineages E (erythroid, CD71+/
Ter119+), M (myeloid, Gr-1+/Mac-1+), T (T cell,
CD3+ or CD4+/CD8+), B (B cell, B220+), and
HSC (Sca-1+, c-kit+) all demonstrate similar distri-
bution within the b-gal compartment (n = 6), aside
from a slight decrease in T cell lineage b-gal ex-
pression over total b-gal population. Data shown
as mean ± SEM. Scale bars, (A), 1 mm; (B) and
(D), 100 mm; (C), (E), and (F), 50 mm.626 Cell Stem Cell 3, 625–636, December 4, 2008 ª2008 Elsevier Inc.
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(A and B) Top panels demonstrate 4OHT levels after maternal injection at either E8.5 (A) or E9.5 (B) based onmeasured sera levels (see Figure S2). Middle panels
depict whole-mount embryos, b-gal in blue; scale bars, 1 mm. Bottom panels demonstrate histological sections of the umbilical artery (UA), vitelline artery (VA),
and AGM at E10.5, b-gal in blue, nuclear counterstain in red; scale bars, 50 mm. ([A], middle) Tamoxifen administration at E8.5 results in minimal vascular labeling
at E10.5 and E11.5. ([A], bottom) Induction at E8.5 results in UA and VA labeling whileminimally labeling the AGM. ([B], middle) Induction at E9.5 exhibits less b-gal
expression at E10.5 but more robust endothelial recombination by E11.5. ([B], bottom) E9.5 induction results in labeling of the AGM, but not the UA and VA at
E10.5.While the aforementioned data suggest that the VE-cadherin
AGM population is capable of definitive adult hematopoiesis, it
cannot exclude the potential contribution of extraembryonic,
yolk sac-derived cells. In fact, it has been demonstrated in the
VE-cadherin Cre mouse (Alva et al., 2006), and other hemangio-
blast studies (Wang et al., 2004; Yokomizo et al., 2007), that the
early yolk sac hematopoietic population includes a significant
subset of VE-cadherin progeny (see Figure S1A available online).
In addition, while there has been longstanding debate as to
whether early yolk sac cells are capable of definitive adult hema-
topoiesis, recent data support this possibility (Samokhvalov
et al., 2007). Thus, to avoid labeling early yolk sac populations
and investigate the VE-cadherin AGM population, an inducible
fate map with time-restricted labeling was utilized.
Notably, VE-cadherin Cre does not label all hematopoietic
cells, as demonstrated in the fetal liver and adult bone marrow
(Figures 1E and 1F). While AGM hematopoietic cells are labeled
in this Cre line, later hematopoietic sites clearly contain an unla-
beled population, which may suggest a nonvascular/non-VE-
cadherin+ hematopoietic source. The VE-cadherin null mouse
exhibits lethality by E9.5–10, with absence of intraembryonic
hematopoiesis (Carmeliet et al., 1999; Gory-Faure et al., 1999),
but with preservation of some yolk sac hematopoiesis (Rampon
and Huber, 2003). Examination of the VE-cadherin null yolk
sac demonstrates disorganized vasculature and accumulation
of hematopoietic cells within underdeveloped vascular lumensCe(Figure S1B). It is unclear whether the yolk sac cells in the
VE-cadherin null mouse represent progeny from primitive or dis-
organized VE-cadherin null vasculature or rather that the cells do
not require VE-cadherin. If the latter is true, it may account for the
unlabeled population in the VE-cadherin Cre fetal liver and adult
bone marrow. Another possibility is that while upstream intronic
sequences of the VE-cadherin promoter are known to enhance
endothelial expression of VE-cadherin (Hisatsune et al., 2005),
the observed unlabeled population may be a reflection of the
promoter used.
Inducible VE-Cadherin Cre Selectively Labels AGM
Endothelium and Midgestation Hematopoiesis
To obtain restricted labeling of VE-cadherin progeny in the AGM
from E10–11.5, when most hematopoietic budding is observed
(Garcia-Porrero et al., 1995), a tamoxifen-inducible VE-cadherin
Cre line (Monvoisin et al., 2006) was crossed to the R26R line
(Soriano, 1999). Tamoxifen is thought to be available for Cre ac-
tivation throughout the first 48 hr after injection (Nakamura et al.,
2006). However, assessment of tamoxifen metabolites in serum
indicates that minimally active levels remain up to 72 hr postdose
(Figure S2, Supplemental Text and Supplemental Experimental
Procedures). Therefore, tamoxifen induction of Cre expression
was investigated during two separate time points to reveal the
optimal period for AGM induction (Figure 2). In addition to the
dorsal aortic endothelium, the vitelline and umbilical arteriesll Stem Cell 3, 625–636, December 4, 2008 ª2008 Elsevier Inc. 627
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Endothelial HematopoiesisFigure 3. Temporal Restriction of Endothelial Tracing by an Inducible VE-Cadherin Cre System
(A) Schema depicting the inducible Cre/R26R lineage tracing system, where Cre remains inactive until tamoxifen (1 mg) is administered at E9.5, resulting in sub-
sequent recombination and labeling during the defined tamoxifen window (12–72 hr).
(B) Histological sections depict constitutive Cre/R26R b-gal labeling of the AGM endothelium at E10.5 (Ba) and traced fetal liver cells at E14.5 (Bb).
(C) (Ca) Identification of b-gal-labeled AGM endothelium and ‘‘budding’’ hematopoietic progeny (arrow) at E11.5, after tamoxifen injection. (Cb) This inducible
system traces a substantial historical population that can be found in the fetal liver at E14.5. (B andC) Scale bars, 50 mm. b-gal activity in blue, nuclear counterstain
in red.also exhibit clusters of hematopoietic cells, prior to the AGM
(Garcia-Porrero et al., 1995; North et al., 1999; de Bruijn et al.,
2000). These arteries are preferentially labeled when induction
is triggered by tamoxifen injection at E8.5 (Figure 2A). The lag
in aortic labeling is also seen in the constitutive VE-cadherin
Cre line where the dorsal aortic endothelium is only partially la-
beled by E9.5 (Alva et al., 2006). Induction at E9.5 demonstrates
significantly reduced labeling of the vitelline and umbilical artery
during their period of hematopoiesis and instead primarily labels
the AGM endothelium and its associated hematopoietic cells
(Figure 2B). However, the umbilical and vitelline vessels are
eventually labeled at E11.5 as the endothelial population ex-
pands (data not shown). The increased vascular labeling at
E11.5 after E9.5 induction, as compared to E8.5 (Figures 2A
and 2B, middle panels), is likely due to a developmental increase
in vascular VE-cadherin Cre expression during this period.
Thus, timed induction of Cre expression was carried out at
E9.5, allowing the tamoxifen ‘‘window’’ to span from E9.5 to
E12.5, encompassing the period of AGM hematopoietic activity
(Figure 3A), while bypassing the period of VE-cadherin expres-
sion in early yolk sac progenitors. A single dose of tamoxifen
(1 mg) was administered via intraperitoneal injection (i.p.) into
pregnant mothers at E9.5, and embryos were evaluated at
E10.5, E11.5, and E14.5, as well as at adult stages. At E10.5,628 Cell Stem Cell 3, 625–636, December 4, 2008 ª2008 Elsevier Invery little recombination was noted, as evidenced by b-gal label-
ing (Figure 2B). By E11.5, the inducible system labeled the dorsal
aortic endothelium and ‘‘budding’’ hematopoietic cells, as
shown in Figure 3Ca. Although the level of recombination did
not match that of the constitutive system (Figure 3B), it was suf-
ficient to allow lineage tracing to the fetal liver at E14.5
(Figure 3Cb). Thus, from the one dose of tamoxifen we were
able to demonstrate recombination (via reporter activity) in the
AGM endothelium by E11.5, with subsequent reporter ex-
pression in attached hematopoietic cells (Figure 3Ca) and later
expansion and migration of the progeny to the fetal liver
(Figure 3Cb).
VE-Cadherin Endothelial Population Gives Rise
to Definitive Adult Hematopoiesis
The definition of a HSC includes its capacity to self-renew, to
give rise to all hematopoietic lineages, and to reconstitute irradi-
ated adult host bone marrow for more than 8 months. The induc-
ible system allows HSC tracking in vivo and thus avoids the re-
moval of cells from their milieu. A small cell population was
labeled during a finite embryonic window (single embryonic in-
jection at E9.5) and followed, in vivo, into adulthood (up to
13 months postnatal age). The bone marrow from this cohort
demonstrated reporter-labeled bone marrow cells constitutingc.
Cell Stem Cell
Endothelial Hematopoiesisanywhere from 2%–24% of total bone marrow cells (Figure 4A).
The wide range is likely due to inherent tamoxifen dose variation
among littermates (Figure S2D). Nonetheless, a large number of
offspring (12 out of 13) demonstrated labeled bone marrow cells
Figure 4. VE-Cadherin Cre Induction at E9.5 Results in Long-Term
Adult Hematopoiesis
(A) Flow cytometry analysis depicts b-gal-labeled cells in adult bone marrow
per animal after embryonic induction, compared to wild-type (WT).
(B) Fold change of b-gal-positive cells per lineage as compared to total (aver-
aged, n = 12). All adult bone marrow lineages are labeled: E (erythroid, CD71+/
Ter119+), M (myeloid, Gr-1+/Mac-1+), T (T cell, CD3+ or CD4+/CD8+), B
(B cell, B220+), and HSC (Sca-1+,c-kit+). This is also seen in a cohort (n = 6)
1 year after induction (data averaged into total pool of 12). Data shown as
mean ± SEM. (Panels) Boxed areas in the left columns are magnified on right.
Histological sections depict b-gal labeling of hematopoietic cells in the adult
bone marrow, thymus, and spleen (n = 4). (Bottom) Labeled endothelial cells
of the aorta (left) and thymus (right) are traced in the adult after embryonic in-
duction. Scale bars, 50 mm. b-gal activity is in blue, nuclear counterstain in red.Ceexhibiting cell-surface markers of all hematopoietic lineages as
well as stem cell markers (Figure 4B, Figure S3). In addition,
a subset of animals (n = 4), were evaluated for the presence of
VE-cadherin progenitors in the spleen and thymus, where la-
beled cells were also noted (Figure 4, panels). Endothelial cells
that were labeled in the embryo also demonstrate progeny in
adult vessels (Figure 4, bottom panels). The fact that cells genet-
ically marked at midgestation have progeny detected as late as
1 year postnatally strongly suggests a stem population. Further-
more, the expression of stem markers Sca-1+/c-kit+ within this
late population, as well as markers identifying all hematopoietic
lineages, demonstrates that the induced VE-cadherin endothe-
lial population is autonomously capable of definitive hematopoi-
esis. In contrast to earlier studies, these data physiologically
demonstrate, in vivo, that a restricted VE-cadherin population
from the endothelium and its associated hematopoietic cells
produce progeny that give rise to adult hematopoiesis.
Fetal Liver VE-Cadherin Population Is Migratory
and Does Not Originate In Situ
Recent studies have indicated that fetal liver HSCs express VE-
cadherin protein (Kim et al., 2005; Taoudi et al., 2005). Thus, we
investigated whether the inducible system inadvertently labels
the fetal liver VE-cadherin population during the active tamoxifen
window (E9.5–12.5). To address this question, fetal liver cells
were induced ex vivo for 24 hr as organ cultures at E10.5,
E11.5, and E12.5. Following 4-hydroxytamoxifen (4OHT) induc-
tion, a subset of fetal livers was cultured in methylcellulose he-
matopoietic colony assays for 1 week (Figure 5A). Cre recombi-
nase induction was measured by both b-gal activity and FACS
analysis of the CD45+ population using a R26R EYFP line (Srini-
vas et al., 2001). In vitro 4OHT induction did not label hematopoi-
etic cells within the fetal liver during any of the time points inves-
tigated (Figure 5C). Instead, labeled vascular structures were
noted that were unable to give rise to hematopoietic cells
(Figure 5C, arrows). This differs from constitutive VE-cadherin
Cre/R26R livers, in which labeled hematopoietic cells were
capable of expanding, both in the organ culture and methylcel-
lulose (Figure 5D). The lack of hematopoietic activity in the
tamoxifen-treated fetal livers also differed significantly from the
AGM endothelial induction and hematopoietic cell labeling
(Figure 5B). To further verify the results of the in vitro system, em-
bryonic lung was also cultured and resulted in exclusively vascu-
lar labeling (Figure S4A). Also of note is the diminished vascular
labeling in the induced fetal liver with increasing age (Figure 5C).
To ensure this was not due to artificially decreased physiologic
VE-cadherin gene expression in vitro, we compared dissected
to cultured fetal livers and noted a slight increase in VE-cadherin
expression within the cultured group (Figure S4B). Thus, the la-
beled hematopoietic population observed within the fetal liver,
in vivo, is a migratory population likely originating from the
AGM. The data are reconciled with previous reports of HSC
VE-cadherin protein expression by understanding that the sys-
tem reflects VE-cadherin promoter activity. Therefore, it is quite
possible that while the VE-cadherin promoter is no longer active
in the early fetal liver hematopoietic population, the protein may
continue to be expressed as a result of promoter activation in the
AGM endothelium. However, shortly thereafter, the surfacell Stem Cell 3, 625–636, December 4, 2008 ª2008 Elsevier Inc. 629
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(A) Organ cultures of fetal liver (or AGM) underwent 24 hr 4OHT in vitro induction using separate lacZ andEYFPCre reporter lines. A subset of cultured organs (livers
and AGMs)were dissociated and cultured inmethylcellulose for 7–10 days, and both organ cultures and cells obtained from hematopoietic assayswere evaluated
for b-gal labeling. Alternatively, cells from hematopoietic assays of the EYFP line underwent FACS analysis of EYFP expression after gating for CD45 expression.
(B–D) Organ cultures are shown in left panels (scale bars, 100 mm) and cells removed from hematopoietic assays in middle panels (scale bars, 50 mm); red arrows in-
dicate endothelialmorphology, black arrowshematopoieticmorphology; b-gal expression in blue. ([B] and [C], right panels) Gated EYFPexpressionwithin theCD45+
compartment. (B) Induction of AGMatE11.5 resulted in both endothelial and hematopoietic b-gal activity (arrows) quantified as 4.27%EYFP-labeledCD45+cells. (C)
When fetal liver is induced for 24hratE10.5,E11.5,andE12.5,b-gal labeling is restricted toapparentendothelial populations thatdonotproducehematopoieticcells in
culture. (D) In contrast, the constitutive system demonstrates b-gal labeling in both hematopoietic and endothelial populations throughout all time points.
(E) Peripheral blood was pooled at E11.0 and induced in vitro for 24 hr in suspension. Cells were then analyzed for EYFP expression within the CD45+ population.
Alternatively, the corresponding AGMs were induced for 24 hr in organ culture, pooled, and analyzed for EYFP expression within hematopoietic (CD45+) and endo-
thelial (PECAM+ CD45) compartments. Only the AGM, with endothelial induction, was capable of producing labeled hematopoietic cells.630 Cell Stem Cell 3, 625–636, December 4, 2008 ª2008 Elsevier Inc.
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nificantly reduced (Kim et al., 2005; Taoudi et al., 2005).
Circulating VE-Cadherin Population Is Derived
from the Endothelium
Much like the fetal liver, circulating cells have also been shown to
express VE-cadherin protein atmidgestation (Taoudi et al., 2005).
To investigate whether cells in the circulation could be induced to
express VE-cadherin Cre and thus alter the interpretation of the
endothelial tracing results, we pooled E11.0 peripheral blood
and cultured the cells overnight in suspension with 4OHT
(Figure 5E). Pooled AGMs from the same embryos were also
4OHT treated overnight in organ culture (Figure 5E). Notably,
only the AGM endothelium (CD45-PECAM-1+) was labeled and
able to produce reporter positive hematopoietic cells (CD45+);
seeFigure 5E. Also of interest is that thepercentage of labeled en-
dothelium (4.81% in Figure 5E) mirrors that of the hematopoietic
population after 1 week of methylcellulose culture (4.27% in
Figure 5B). This suggests that the labeled hematopoietic popula-
tion capable of self-renewal and expansion is proportional to the
inductionof theendothelial population. In vitro inductionofperiph-
eral blood at ages E10.5 and E12.5 also resulted in lack of recom-
bination within the hematopoietic population (data not shown).
Lastly, when E10.5 circulating blood is evaluated for relative VE-
cadherin mRNA expression, it has less expression than control
mouse embryonic fibroblasts (Figure S4C). This further suggests
that previously reported VE-cadherin protein expression in pe-
ripheral blood (Taoudi et al., 2005) is likely historical following an
endothelial origin and not due to concurrent gene expression.
Other Endothelial Populations Are Capable
of Hematopoiesis
While our in vivo induction strategy was capable of focused AGM
labeling in lieu of the vitelline and umbilical arteries, the placental
vasculature was also labeled within our defined tamoxifen win-
dow (Figure S5A). As the placental vasculature has recently
been suggested to be a source of hematopoiesis (Alvarez-Silva
et al., 2003; Rhodes et al., 2008), we undertook a similar
in vitro strategy of induction (Supplemental Experimental Proce-
dures). During this period, while not as robust as the AGM
(Figure 5B), our data support the concept that the placental en-
dothelium is also a source of hematopoietic cells (Figure S5B).
The early yolk sac (E7–7.5) has also been shown to produce
hematopoietic populations that express VE-cadherin with possi-
ble definitive potential (Samokhvalov et al., 2007; Yokomizo
et al., 2007). Our lineage tracing strategy avoids labeling this
early population. Later in gestation, the yolk sac has been shown
to contain definitive HSCs that are not thought to arise in situ
(Cumano et al., 2001). Interestingly, using organotypic in vitro in-
duction of the yolk sac at E10.5, E11.5, and E12.5, we observed
endothelial-derived hematopoietic cell emergence (Figure S6).
These results are in agreement with earlier studies that demon-
strated the hematopoietic potential of yolk sac side population
cells from E9.5 to E11.5 (Nadin et al., 2003).
The AGM Hematopoietic Population Is Endothelial
Derived
The ability to lineage trace the VE-cadherin AGM population re-
sults from the fact that AGM hematopoietic cells are not only inCecontact with the endothelium, which canonically expresses VE-
cadherin, but also that the hematopoietic cells retain reporter ac-
tivity. This relationship, along with our in vitro induction studies,
suggests the emergence of hematopoietic cells from the endo-
thelium. However, there also exists evidence that the underlying
mesenchyme of the AGM regionmay also give rise to HSCs (Ber-
trand et al., 2005). To address this issue, we assayed various
‘‘mesenchymal/smooth muscle’’ Cre lines that demonstrate
a spectrum of Cre expression. The spectrum reflects the com-
plexity of vascular smooth muscle origins (reviewed in Majesky,
2007). During midgestation, the undifferentiated mesenchyme of
the aorta has recently been shown to contain at least two sepa-
rate mesenchymal populations. The first originates from
a splanchnic lateral plate mesoderm and is later replaced by
sclerotomal-derived mesoderm (Wiegreffe et al., 2007; Pouget
et al., 2008; Wasteson et al., 2008).
Our initial studies focused on both the constitutive and tamox-
ifen-inducible smoothmuscle 22apromoter (SM22a) Cre recom-
binase lines (Kuhbandner et al., 2000; Holtwick et al., 2002).
SM22a is expressed in adult visceral and vascular smooth mus-
cle, and temporarily in embryonic cardiac and somiticmesoderm
(Li et al., 1996; Zhang et al., 2001). SM22a expression is thought
to represent differentiated smooth muscle phenotypes later in
development and in the adult (Li et al., 1996; Wasteson et al.,
2008). However, SM22a is also noted in mesenchymal popula-
tions surrounding the aorta as early asE9.0 (Li et al., 1996). During
AGM development, the constitutive SM22a Cre labeled both the
underlying mesenchyme and the endothelium, resulting in long-
term labeling of both the adult aortic endothelium and adult
bone marrow cells (Figure 6A). This finding was confirmed in
a separate SM22a Cre recombinase line obtained from our col-
laborators andwas likely a result of labeling early aorticmesoder-
mal lineages known to have the capacity to differentiate into en-
dothelium (Wasteson et al., 2008). To investigate whether the
endothelial (and subsequent hematopoietic) labeling could be
avoidedby tracking later SM22amesodermal lineages,we inves-
tigated a tamoxifen-inducible SM22aCre line. Timed induction at
E9.5 demonstrates a decrease in endothelial b-gal expression
but still resulted in hematopoietic labeling (Figure 6A). The phe-
nomenon is developmentally related, as induction in the adult
does not result in endothelial or hematopoietic labeling
(Figure S7A). Therefore, it appears that SM22a is expressed in
both early and late mesodermal populations that reside in the
subaortic floor. However, the former contributes to the endothe-
lium of this region and thus precludes the ability to distinguish the
properties of the latter. This may also be the case for other endo-
thelial niches, as the yolk sac and placental endothelium appear
labeled in the SM22a lineage (Figure S7B). It should be noted that
while SM22a Cre is expressed in the aortic endothelium, it is not
detected in the endothelial cells of other adult vascular beds
(Figure 6C).
Myocardin, a transcriptional cofactor in smoothmuscle cell dif-
ferentiation, is noted to be predominately expressed in cardiac
and smooth muscle cells (Wang et al., 2001). However, develop-
mentally, it is also a marker of somitic mesoderm, as myocardin
Cre expression is found in dermamyotome and sclerotome pop-
ulations (Long et al., 2007). The latter sclerotome population is
implicated as a progenitor to the ‘‘replacement’’ vascular smooth
muscle cells of the aorta (Wasteson et al., 2008). As a result,ll Stem Cell 3, 625–636, December 4, 2008 ª2008 Elsevier Inc. 631
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Endothelial HematopoiesisFigure 6. Subaortic Mesenchyme Does Not Contribute to Hematopoiesis, except through an Endothelial Intermediate
(A–C) Labeled cells depicted by arrows, unlabeled cells depicted by arrowheads. ([A], top panel) SM22a Cre crossed with the R26R lacZ reporter line demon-
strates labeling not only in the subaortic mesenchyme of the AGM (E11.5) but also within the endothelial layer. The endothelial labeling persists in the adult aorta
and results in labeled hematopoietic cells in the adult bone marrow by histology and FACS of b-gal expression (31.49% of CD45+ population). ([A], bottom panel)
To restrict SM22a Cre labeling to a period during AGM hematopoiesis, a tamoxifen-inducible SM22a Cre was employed and induced at E9.5. While the mesen-
chymal contribution to the endothelium was decreased in the AGM (E11.5), there remained a population of labeled endothelium and subsequent hematopoietic
cells (10.77%) in the adult. (B) Myocardin Cre crossed to a R26R lacZ reporter line demonstrates labeling of the AGMmesenchyme at E11.5, without contribution
to the AGM or adult aortic endothelium, and absence of any hematopoietic contribution to adult bone marrow (0.58% with 1.36% WT background in FACS-gal
assay). (C) Whole-mount SM22aCre and VE-cadherin Cre embryos at E10.5 demonstrate similar b-gal staining pattern in the dorsal aorta (arrowheads), but not in
the intersomitic or surface vessels (arrows). When the two Cre lines are compared in adult vascular beds, the smooth muscle layers are labeled in the SM22a line
(arrows), but not in the VE-cadherin line (arrowheads). In contrast, the endothelial layer is labeled in the VE-cadherin Cre (arrows), but not the SM22a Cre (arrow-
heads). (A–C) b-gal activity depicted in blue, nuclear counterstain in red. Scale bars, 50 mm, unless otherwise specified.632 Cell Stem Cell 3, 625–636, December 4, 2008 ª2008 Elsevier Inc.
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Endothelial Hematopoiesismyocardin Cre is notably expressed in AGM subaortic mesen-
chyme, but not endothelium (Figure 6B). When followed into
adulthood, the absence of endothelial labeling results in lack of
b-gal hematopoietic expression (Figure 6B). Thus, the subaortic
mesenchyme is unable to directly give rise to HSCs, and only
through an endothelial intermediate can hematopoiesis occur.
DISCUSSION
The time of onset and anatomical location of definitive hemato-
poiesis have been studied with equal parts rigor and conten-
tiousness. Many approaches have been employed, which have
included physically separating areas of hematopoiesis and
maintaining them in vitro. While the information gained from
Figure 7. Midgestation HSCs Are Endothe-
lial Derived
(A) Runx1, a transcription factor critical for defini-
tive hematopoiesis, is expressed in both the
AGM endothelium and mesenchyme as exhibited
by the Runx1-lacZ transgenic mouse line. When
AGM endothelium is selectively labeled using the
inducible VE-cadherin Cre crossed to a R26R
lacZ reporter line, HSCs are traced to adult bone
marrow. However, when the AGM subaortic mes-
enchyme is selectively labeled, hematopoietic
cells are not labeled in the adult bone marrow.
Scale bars, 10 mm.
(B) Endotheliummaintains hematopoietic capacity
in the AGM. The early transientmesenchymal pop-
ulation of the AGM contributes to the endothelium
and subsequently to hematopoiesis. Later AGM
mesenchymal populations do not have endothelial
potential and therefore do not have hematopoietic
capacity.
these studies has been invaluable, ques-
tions remained as to the potential of the
studied populations in vivo, the cell types
responsible for definitive hematopoiesis,
and whether a distinct intraembryonic
population could autonomously give rise
to adult lineages. Lineage tracing allows
specific cell populations to be mapped
in vivo, and in the current study has dem-
onstrated that the VE-cadherin lineage of
the AGM (and possibly the placenta and
yolk sac) is capable of long-term, multili-
neage adult hematopoiesis. In addition,
the induction of VE-cadherin promoter-
driven Cre activity ex vivo demonstrates
that while HSCs in the circulation and fe-
tal liver may express VE-cadherin protein
(Kim et al., 2005; Taoudi et al., 2005),
these populations do not demonstrate
activity of the VE-cadherin promoter.
The VE-cadherin protein expression
within these populations is therefore
a likely consequence of their descent
from the endothelium, which constitutively expresses both the
VE-cadherin promoter and protein (Breier et al., 1996).
The debate as to which cell type is responsible for AGM HSC
emergence (endothelium or mesenchyme) lies in the diverse
characteristics of the region. Runx1, a transcription factor re-
quired for definitive hematopoiesis, is broadly expressed in
AGM hematopoietic cells, endothelium, and underlying mesen-
chyme (Figure 7A) (Wang et al., 1996; North et al., 1999; Cai
et al., 2000). While many cell-surface proteins are shared be-
tween the endothelium and their attached hematopoietic cells
in this region (including PECAM, CD34, and VE-cadherin) (North
et al., 2002; Bollerot et al., 2005), hematopoietic markers (AA4.1,
GATA-3) are also expressed in mesenchymal subaortic patches
(Bertrand et al., 2005). Unfortunately, the timing and sequence ofCell Stem Cell 3, 625–636, December 4, 2008 ª2008 Elsevier Inc. 633
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Endothelial HematopoiesisHSC cell marker expression as cells emerge from this region is
not known, making it difficult to conclude whether the subaortic
patches are supporting or giving rise to HSCs. However, when
the critical Runx1 gene is ablated in endothelium and accompa-
nying hematopoietic cells, definitive hematopoiesis is halted
(Li et al., 2006).
Our ability to selectively lineage trace both the endothelium
and mesenchyme separately allowed us to demonstrate that in-
deed the endothelium is responsible for HSC emergence in this
region (Figure 7A). However, the task of selectively labeling the
underlying mesenchyme, in lieu of the endothelium, was more
difficult than initially anticipated. SM22a, a cytoskeletal protein
expressed exclusively in visceral and vascular smooth muscle
during postnatal development, also labels early aorticmesoderm
in the embryo (Zhang et al., 2001). When indelibly tagged using
a constitutive or an inducible SM22a Cre, this mesoderm is
found to contribute to the endothelial floor of the dorsal aorta.
This correlates with recent data of aortic floor formation in both
avian and murine systems (Pouget et al., 2006; Wiegreffe et al.,
2007; Wasteson et al., 2008). The mesenchymal floor of the
AGM region is shown to be transiently formed by lateral plate
mesoderm capable of contribution to the aortic endothelium
(Wasteson et al., 2008). The mesenchymal population is then re-
placed by a second population, derived from sclerotomal meso-
derm, that migrates from the dorsal and lateral walls to the ven-
tral side of the aorta (Wiegreffe et al., 2007; Pouget et al., 2008;
Wasteson et al., 2008). This second wave migration of mesen-
chymal cells closely mirrors the developmental pattern of myo-
cardin Cre lineages in the embryonic aorta (Long et al., 2007).
As evidenced here, in the myocardin Cre line, this second popu-
lation does not contribute to the endothelium. Therefore, SM22a
Cre labels both early and late mesodermal populations, while
myocardin Cre labels the later permanent population, thus en-
abling the tracing of early and late populations and their subse-
quent hematopoietic potential. By doing so, we have demon-
strated that only the early mesenchymal population, which
contributes to the aortic floor endothelium (and placental and
yolk sac vasculature, Figure S7), has the capacity for hematopoi-
esis and does so via an endothelial intermediate (Figure 7B).
The fact that the endothelium responsible for hematopoiesis,
e.g., hemogenic endothelium, appears to develop from a tran-
sient early mesenchymal lineage imparts a specialization to the
endothelium. Yet, its hematopoietic capacity is fleeting, much
like the initial population of the underlying AGM mesenchyme.
It may be that the manifestation of hemogenic endothelium
requires not only specified endothelium but also a specialized
niche within the underlying mesenchyme. The complex orches-
tration of signaling between AGMmesenchyme and endothelium
remains to be dissected. However, our data provide in vivo
physiologic evidence that endothelium is responsible for stem
cell emergence within the AGM region, and furthermore that
this endothelium is derived from a transient mesenchymal
population.
EXPERIMENTAL PROCEDURES
Animals
Animals were housed and animal protocols conducted in accordance with
University of California, Los Angeles (UCLA) Animal Research Committee634 Cell Stem Cell 3, 625–636, December 4, 2008 ª2008 Elsevier Inguidelines. VE-cadherin Cre and inducible VE-cadherin Cre mice, described
elsewhere (Alva et al., 2006; Monvoisin et al., 2006), were crossed to R26R
Cre reporter lines with lacZ reporter (Soriano, 1999) and separately EYFP re-
porter (Srinivas et al., 2001). SM22a Cre (Holtwick et al., 2002) was obtained
from Jackson laboratories, and tamoxifen-inducible SM22a Cre (Kuhbandner
et al., 2000) was a generous gift from Robert Feil (Institute of Pharmacology
and Toxicology, Germany). An additional SM22a Cre/R26R lacZ line was pro-
vided by Michelle Tallquist (UT Southwestern, Dallas, TX). The myocardin Cre/
R26R lacZ line (Long et al., 2007) was provided by Eric Olson (UT Southwest-
ern, Dallas, TX). The Runx1-lacZ (North et al., 1999) reporter line was provided
by Nancy Speck (Dartmouth Medical School, Hanover, NH). Pregnancies were
dated by observance of a vaginal plug (gestation day 0.5 on day of plug). Ta-
moxifen (ICN) was prepared as described (Monvoisin et al., 2006), and preg-
nant females were injected with 1 mg (100 ml) i.p. at E9.5 (or E8.5 for AGM tim-
ing experiments). Embryos that were followed to adulthood underwent
Cesarean section if the mother was unable to give birth naturally. The pups
were then fostered with other females. A minimum of three litters was investi-
gated for all VE-cadherin Cre (constitutive and inducible) time points, n = 12–13
adults. For SM22a Cre and myocardin Cre lines, n = 2–3 litters, n = 2–5 for
adults, and iSM22Cre adult n = 1.
b-Gal Activity and Immunohistochemistry
b-gal staining and histology were carried out as previously described (Alva
et al., 2006). Vibratome sections (400 mm) of E13.5–E14.5 embryos were fixed
in 2% paraformaldehyde, then incubated with 1:100 VE-cadherin monoclonal
rat anti-mouse antibody BV13/4 (generous gift from ImClone Systems, Inc.)
and 1:200 Cy3 secondary antibody (Jackson ImmunoResearch). For myocar-
din Cre sections, embryos were fixed in 2% formaldehyde/0.2% glutaralde-
hyde and embedded in OCT. Ten micron sections were then stained in X-gal
following standard protocols.
Flow Cytometry
FACS analysis of b-gal was carried out as described (Monvoisin et al., 2006).
Tissues underwent mechanical dissociation by pipetting to single-cell suspen-
sion. Cells were analyzed on a FACSCalibur with the following monoclonal an-
tibodies: Sca-1-PE (E13–161.7), c-kit-APC (2B8), AA4.1-PE, CD34-APC
(RAM34), TER119-APC, CD71-PE (C2), Mac1-APC (M1/70), Gr-1-PE (8C5),
CD3-APC (2C11), CD4-PE (GK1.5), CD8-APC (53-6.7), B220-PE (62B),
CD45-APC (F11), PECAM-1-PE (MEC 13.3), and 7-AAD (7-amino-actinomycin
D) for viability. All monoclonal antibodies, their appropriate isotype controls,
and 7-AAD were purchased from BD Pharmingen.
Organ Culture and Hematopoietic Assays
Fetal livers from E10.5, E11.5, and E12.5 (and E11.5 AGM) were dissected and
cultured for 24 hr on 40 mm filters at an air-liquid interface, as described (Med-
vinsky and Dzierzak, 1996), in myelocult media (Stem Cell Technologies), sup-
plemented with 106 M hydrocortisone (Stem Cell Technologies) and 10 mMof
4OHT (Sigma). A subset of cultured organs underwent b-gal staining (n = 3),
while the rest were mechanically dissociated and plated at 4 3 103 cells/ml
in Methocult M3434 methylcellulose media (Stem Cell Technologies) for ap-
proximately 1 week (n = 3). After colonies were expanded, cells were removed
from culture, resuspended, and X-gal stained. Alternatively, for EYFP lines,
cells were stained for CD45-APC and 7-AAD and analyzed for EYFP expres-
sion by FACS (gated on CD45+ and 7-AAD).
In Vitro 4OHT Induction of Peripheral Blood
Inducible VE-cadherin Cre crossed to EYFP R26R litters of E10.5, E11.0–11.5,
and E12.5 (pooled separately, n = 3 litters each) were bled in warm PBS after
removal of embryos from their respective yolk sacs and placentas. The periph-
eral blood cells were pelleted and resuspended in the same media used in the
fetal liver assays (above) with 10 mM of 4OHT (Sigma) for 24 hr. The cells were
then stained for CD45-APC and 7-AAD and analyzed for EYFP expression by
FACS (gated on CD45+ and 7-AAD). Alternatively, the AGMs from the same
litter at E11.0 were cultured on 40 mm filters (as described above) for 24 hr in
4OHT and then pooled and analyzed for EYFP expression by FACS (gated
for hematopoietic cells, CD45+ and 7-AAD; or endothelium, PECAM+CD45
and 7-AAD).c.
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